Novo Nordisk's rare disease segment boosted by hemophilia treatments in Q3
Total sales of the Danish company’s treatments for rare diseases, which include bleeding disorders, grew to DKK 5.1bn (USD 679m) in the year’s third quarter.
by marketwire, translated by daniel pedersen
Novo Nordisk’s third-quarter sales of Novoseven, a hemophilia treatment, surprised positively in a quarter where the Danish drugmaker’s revenues from its rare disease segment also increased.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance after sales increase
For subscribers
Novo Nordisk on track to secure Wegovy doses
For subscribers
